Biological Effects of Phosphocitrate on Osteoarthritic Articular Chondrocytes

Yubo Sun*, Atiya M Franklin, David R Mauerhan and Edward N Hanley

Department of Orthopedic Surgery, Cannon Research, Carolinas Medical Center, PO Box 32861, Charlotte, NC 28232, USA

Received: January 30, 2017 Revised: March 06, 2017 Accepted: April 08, 2017

Abstract:

Background: Phosphocitrate (PC) inhibits osteoarthritis (OA) in Hartley guinea pigs. However, the underlying molecular mechanisms remain poorly understood.

Objective: This study sought to examine the biological effect of PC on OA chondrocytes and test the hypothesis that PC may exert its OA disease modifying effect, in part, by inhibiting the expression of genes implicated in OA disease process and stimulating the production of extracellular matrices.

Method: OA chondrocytes were cultured in the absence or presence of PC. Total RNA was extracted and subjected to microarray analyses. The effect of PC on proliferation and chondrocyte-mediated calcification were examined in monolayer culture. The effect of PC on the production of extracellular matrices was examined in micromass culture.

Results: PC downregulated the expression of numerous genes classified in proliferation and apoptosis while upregulating the expression of many genes classified in transforming growth factor-β (TGF-β) receptor signaling pathway and ossification. PC also downregulated the expressions of many genes classified in inflammatory response and Wnt receptor signaling pathways. Consistent with its effect on the expression of genes classified in proliferation, ossification, and skeletal development, PC inhibited the proliferation of OA chondrocytes and chondrocyte-mediated calcification while stimulating the production of extracellular matrices.

Conclusion: PC may exert its OA disease modifying effect, in part, through a crystal-independent mechanism or by inhibiting the expressions of many genes implicated in OA disease process, and at the same time, stimulating the expression of genes implicated in chondroprotection and production of extracellular matrices.

Keywords: Chondrocyte, Calcification, Matrix, Microarray, Osteoarthritis, Phosphocitrate.

1. INTRODUCTION

Osteoarthritis (OA) is a degenerative joint disease characterized by gradual loss of articular cartilage, formation of osteophytes, and synovial inflammation. Existing pharmacological interventions for OA remain insufficient.
prescribed non-steroid anti-inflammatory drugs and steroid knee injections only relieve pain and inflammation but have no effects on the progression of cartilage degeneration. There is a need for the development of structural disease-modifying drugs that not only relieve pain and inflammation but also inhibit or halt the progression of cartilage degeneration. The lack of progress in the development of structural disease-modifying drugs is largely due to our limited understanding of the pathogenesis of OA and insufficient knowledge regarding the molecular targets for therapeutic intervention.

The biochemical events involved in the initiation and progression of OA are poorly understood. Extracellular matrix degrading enzymes and inflammatory cytokines, including matrix metalloproteinases (MMPs), ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5), interleukin-1 (IL-1), and tumor necrosis factor alpha (TNF-α) have been implicated in OA. Small molecules and biologics targeting MMPs, IL-1, and TNF-α have been examined for OA intervention, however, results of clinical trials with MMP inhibitor(s) and biologies against IL-1 and TNF-α were disappointing [1 - 4]. Pathological calcification has also been implicated in OA. Basic calcium phosphate (BCP) crystals and calcium pyrophosphate dihydrate (CPPD) crystals are present in the synovial fluid, menisci, and articular cartilage of patients with end-stage OA [5 - 7]. These crystals stimulated mitogenesis and the production of MMPs and inflammatory cytokines in cell cultures [8 - 11] and induced a severe inflammatory response within the joints of dogs and mice [12, 13].

Phosphocitrate (PC) is a powerful calcification inhibitor, inhibiting calcification or formation of calcium crystals by binding to amorphous calcium phosphate aggregates and the surface of calcium crystals. PC inhibited BCP crystal-induced mitogenesis, expression of MMPs, and cell death [14 - 16]. Based on these findings, a hypothesis that PC is potentially a disease-modifying drug for calcification-induced OA therapy was postulated [17]. A subsequent study demonstrated that PC inhibited meniscal calcification and that the reduction in meniscal calcification was accompanied with decreased cartilage degeneration in Hartley guinea pigs [18]. It was believed that PC exerted its disease modifying activity by inhibiting the formation of calcium crystals and the detrimental interactions between these crystals and joint cells (a crystal-dependent mechanism) [17].

We recently demonstrated that PC downregulated the expression of many genes classified in cell proliferation, angiogenesis, and inflammatory response in the absence of calcium crystals in OA fibroblast-like synoviocytes (FLSs) and OA meniscal cells [19 - 21]. These newer findings suggest that PC exerts its OA disease-modifying activity, in part, through a crystal-independent mechanism, directly acting on OA cells instead of acting on calcium crystals. Indeed, PC inhibited cartilage degeneration in Hartley guinea pig model of posttraumatic OA through both a crystal-dependent mechanism and a crystal-independent mechanism [22]. However, the molecular mechanisms remain poorly understood. In this study, we sought to examine the biological effects of PC on OA articular chondrocytes and test the hypothesis that PC may exert its OA disease modifying effect, in part, by inhibiting the expression of genes implicated in OA disease process and stimulating the production of extracellular matrices. The information gained from this study may not only shed light on the molecular mechanism underlying the OA disease-modifying activity of PC and provide information valuable for the identification of potential disease candidate genes but also may provide information valuable for a better understanding of the pathogenesis of OA.

2. MATERIALS AND METHODS

Dulbecco’s modified eagle medium, StemPro osteogenesis differentiation medium, StemPro chondrogenesis differentiation medium, fetal bovine serum, Hank’s balanced salt solution, antibiotic and antimitotic solution were products of Invitrogen (Carlsbad, CA). Human foreskin fibroblasts were obtained from American Type Culture Collection (CRL-2429, Manassas, VA). PC was synthesized according to the procedures described [23]. In all experiments, 1mm PC was used because it has been used in previous studies and shows no toxic effect on cells [15, 19].

2.1. OA Articular Chondrocytes

OA chondrocytes were prepared from articular cartilage specimens collected from 6 end-stage OA patients (age range of 62-68) undergoing joint replacement surgery at Carolinas Medical Center with the approval of the authors’ Institutional Review Board. The need for informed consent was waived because those specimens were surgical waste, and no private patient information was collected. Articular cartilage was evaluated as described [24], and only grade 4 cartilages were used. Briefly, articular cartilage was removed from the medial tibia plateau with a surgical blade, minced into small pieces, and cultured in 60 mm plates at 37°C in medium containing 10% serum and 0.5% antibiotic/antimitotic solution. Media was changed every 3 days. After chondrocytes reached to 70% confluence, they
were passaged. Chondrocytes with 2-3 passages were used in the study.

2.2. Effect of PC on Gene Expressions

OA chondrocytes derived from 3 OA patients were harvested from 60 mm cell culture plates, mixed, and re-plated in 60 mm plates at 90% confluence (passage 2; 9 x 10⁶ per plate). On the second day, medium containing 1% serum was added. On the third day, medium in 2 plates was replaced with medium containing 1% serum and 1 mM PC and medium in the other 2 plates were replaced with medium containing 1% serum without PC as a control. Twenty-four hours later, total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) and purified using the Oligotex kit (Qiagen, Valencia, CA). The quality and integrity of these RNA samples were checked using RNA 6000 Nano Assay Reagent Kit and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).

RNA samples extracted from two independent experiments were used for microarray analyses. Briefly, double-stranded DNA was synthesized using SuperScript Double-Stranded cDNA Synthesis Kit (Invitrogen, San Diego, CA, USA) using 1 μg of each RNA sample. The DNA product was purified using a GeneChip sample cleanup module (Affymetrix, Santa Clara, CA, USA). CRNA was synthesized and biotin labeled using BioArray high yield RNA transcript labeling kit (Enzo Life Sciences, Farmingdale, NY, USA). The cRNA product was purified using GeneChip sample cleanup module and subsequently chemically fragmented. The fragmented and biotinylated cRNA was hybridized to HG-U133_Plus_2.0 gene chip using Affymetrix Fluidics Station 400 (Affymetrix, Santa Clara, CA, USA). The fluorescent signals were quantified during two scans by Agilent Gene Array Scanner G2500A (Agilent Technologies, Santa Clara, CA, USA). Genesifter (VizX Labs, Seattle, WA, USA) was used for the analysis of differential gene expression and gene ontology. The results of the two microarray experiments were similar, therefore, we focused on the results of the first microarray experiment in this study.

2.3. Real-time RT-PCR

The RNA samples used in microarray experiments were used for real-time RT-PCR. Briefly, cDNA was synthesized using TaqMan® Reverse Transcription Reagents (Applied Biosystems, University Park, IL) using 1 μg RNA sample. Quantification of relative transcript levels of selected genes and the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was performed using TaqMan® Gene Expression assay and ABI7000 Real-Time PCR system (Applied Biosystems, University Park, IL). CDNA samples were amplified with an initial Taq DNA polymerase activation step at 95°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 15 seconds and annealing at 60°C for one minute. Fold change was calculated and the expression level of a specific gene was normalized to the expression level of GAPDH.

2.4. Effect of PC on the Proliferation of OA Chondrocytes

OA chondrocytes (2x10⁵) were plated in six-well cluster plates and cultured in medium containing 10% serum in the absence (triplicates) or the presence of 1 mM PC (triplets). The medium was changed every three days until the chondrocytes in the wells without PC reached to 85% confluence (it took about 14-16 days). Chondrocytes in all wells were harvested and cell numbers counted. This experiment was repeated three times using OA chondrocytes derived from 3 different OA patients. Trypan blue test was performed to examine the effect of PC on chondrocyte viability. Since foreskin fibroblasts were used in many previous studies to determine the effect of PC on crystal-induced mitogenesis and expression of MMPs [15, 25, 26], foreskin fibroblasts were also used here for comparison.

2.5. Effect of PC on Chondrocyte-Mediated Calcification

OA chondrocytes were plated in twenty-four well cluster plates at 90% confluence (7 x 10⁵ cells). On the second day, the medium was replaced with StemPro osteogenesis differentiation medium with or without 1 mm PC (triplicates). These chondrocytes were fed with StemPro osteogenesis differentiation medium with or without PC every three days. Fourteen days later, the media were removed and calcium deposition was examined using alizarin red. This experiment was repeated 6 times using OA chondrocytes derived from 6 different OA patients.

2.6. Effect of PC on the Production of Extracellular Matrices in Micromass Culture

Micromasses were prepared as described previously [7, 27]. Briefly, OA chondrocytes were harvested from 60 mm culture plates and suspended in DMEM containing 10% serum. For preparing a micromass, a droplet of the cell
suspension containing $2 \times 10^5$ chondrocytes was placed in a well of a 24-well cluster plate. After placing all droplets, the plate was incubated for 4 hours at 37°C in a tissue culture incubator and each of the micromasses formed was then fed with StemPro chondrogenesis differentiation medium. Starting on the next day, these micromasses were fed with StemPro chondrogenesis differentiation medium with PC (1 mM) or without PC every three days.

Fourteen days later each well was rinsed twice with 500 μl of Hank’s balanced salt solution and two drops of eosin were added. Five minutes later, eosin was aspirated off and the micromasses were transferred to a strip of filter paper which sat on the top of an ethanol-soaked sponge within a plastic cassette. The cassettes sat in a 10% formalin solution for one hour. These micromasses then underwent routine paraffin embedding. Sections were cut at 5 μm thick and stained with picrosirius red for collagens and alcian blue for proteoglycans. This experiment was repeated 3 times using OA chondrocytes derived from 3 different patients.

2.7. Statistical Analysis

Results are expressed as the mean ± standard error. The difference between the PC-treated and untreated group was analyzed using Student's t-test. It was considered significant when the p-value was < 0.01. Statistical analysis was performed using the statistical analysis tool in the Sigma Plot software, version 12 (Systat software Inc., San Jose, CA).

3. RESULTS

3.1. Effect of PC on Gene Expressions

Of more than 50,000 transcripts, 558 transcripts displayed differential expression (more than 1.5 fold changes) in PC-treated OA chondrocytes compared to untreated OA chondrocytes. A total of 334 transcripts displayed decreased expression and 224 transcripts displayed increased expression. The genes that fell into specific biological processes implicated in OA or suspected to have a role in OA are listed in (Tables 1 and 2).

Table 1. Differentially expressed genes in PC-treated via untreated OA chondrocytes.

| Biological process | Gene ID    | Gene Identifier | Fold change* | Description                                      |
|--------------------|------------|-----------------|--------------|--------------------------------------------------|
| Cell proliferation | HELLS      | NM_018063       | -2.32        | Helicase, lymphoid-specific                       |
|                    | NDP        | NM_000266       | -2.30        | Norrie disease (pseudoglioma)                    |
|                    | EREG       | NM_001432       | -2.18        | Epiregulin                                       |
|                    | KIF15      | NM_020242       | -1.98        | Kinesin family member 15                         |
|                    | SPRY2      | NM_005842       | -1.92        | Sprouty homolog 2 (Drosophila)                   |
|                    | ENPP7      | AA701973        | -1.91        | Ectonucleotide pyrophosphatase/phosphodiesterase 7 |
|                    | E2F7       | AI341146        | -1.87        | E2F transcription factor 7                       |
|                    | IL7        | NM_000880       | -1.82        | Interleukin 7                                    |
|                    | UHRF1      | AK025578        | -1.78        | Ubiquitin-like with PHD and ring finger domains 1 |
|                    | CDK5R1     | AL567411        | -1.75        | Cyclin-dependent kinase 5, regulatory subunit 1 (p35) |
|                    | TACC3      | NM_006342       | -1.75        | Transforming, acidic coiled-coil containing protein 3 |
|                    | NTN1       | BF591483        | -1.75        | Netrin 1                                         |
|                    | EEF1E1     | N32257          | -1.74        | Eukaryotic translation elongation factor 1 epsilon 1 |
|                    | TCF19      | BC002493        | -1.74        | Transcription factor 19                          |
|                    | GINS1      | NM_021067       | -1.73        | GINS complex subunit 1 (Psf1 homolog)           |
|                    | NR2F2      | AL554245        | -1.72        | Nuclear receptor subfamily 2, group F, member 2   |
|                    | CCND1      | BC000076        | -1.68        | Cyclin D1                                       |
|                    | SOX4       | A1989477        | -1.67        | SRY (sex determining region Y)-box 4             |
|                    | MEF2C      | N22468          | -1.66        | Myocyte enhancer factor 2C                       |
|                    | CDKN2D     | U20498          | -1.63        | Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) |
|                    | HBEFG      | NM_001945       | -1.62        | Heparin-binding EGFlike growth factor            |
|                    | FOSL1      | BG251266        | -1.58        | FOS-like antigen 1                               |
|                    | MK167      | AU152107        | -1.58        | Antigen identified by monoclonal antibody Ki-67  |
|                    | TRIM24     | NM_015905       | -1.57        | Tripartite motif-containing 24                    |
|                    | SPHK1      | NM_021972       | -1.56        | Sphingosine kinase 1                             |
| Biological process | Gene ID | Gene Identifier | Fold change* | Description |
|--------------------|---------|-----------------|--------------|-------------|
| Biomedical         | BLM     | NM_000057       | -1.55        | Bloom syndrome, RecQ helicase-like |
|                    | BMP2    | NM_001200       | -1.55        | Bone morphogenetic protein 2 |
|                    | ACER3   | R12678          | -1.55        | Alkaline ceramidase 3 |
|                    | CDCA7   | AY029179        | -1.52        | Cell division cycle associated 7 |
|                    | CDC20   | NM_001255       | -1.50        | Cell division cycle 20 homolog (S. cerevisiae) |
|                    | B4GALT1 | M22921          | 2.20         | UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 1 |
|                    | FGFR2   | M80634          | 1.99         | Fibroblast growth factor receptor 2 |
|                    | EGR1    | A1459194        | 1.98         | Early growth response 1 |
|                    | TXNIP   | AA812232        | 1.82         | Thioredoxin interacting protein |
|                    | TGFBR1  | AV700621        | 1.74         | Transforming growth factor, beta receptor 1 |
|                    | DDR2    | AA545764        | 1.58         | Discoidin domain receptor tyrosine kinase 2 |
|                    | CSF1    | U22386          | 1.55         | Colony stimulating factor 1 (macrophage) |
|                    | IGFBP5  | R73554          | 1.53         | Insulin-like growth factor binding protein 5 |
|                    | ARHIH2  | AW074830        | 1.51         | Ariadne homolog 2 (Drosophila) |
| Apoptosis          | HLLS    | NM_018063       | -2.32        | Helicase, lymphoid-specific |
|                    | DUSP6   | BC003143        | -2.30        | Dual specificity phosphatase 6 |
|                    | SPRY2   | NM_005842       | -1.92        | Sprouty homolog 2 (Drosophila) |
|                    | PCGF2   | NM_007144       | -1.89        | Polycomb group ring finger 2 |
|                    | IL7     | NM_000880       | -1.82        | Interleukin 7 |
|                    | BIRC5   | AA648913        | -1.76        | Baculoviral IAP repeat-containing 5 |
|                    | CDK5R1  | AL567411        | -1.75        | Cyclin-dependent kinase 5, regulatory subunit 1 (p35) |
|                    | RASSF5  | BC004270        | -1.75        | Ras association (RatGDS/AF-6) domain family member 5 |
|                    | NTN1    | BF591483        | -1.75        | Netrin 1 |
|                    | EEF1E1  | N22527          | -1.74        | Eukaryotic translation elongation factor 1 epsilon 1 |
|                    | PAK1    | AU147145        | -1.73        | P21 protein (Cdc42/Rac)-activated kinase 1 |
|                    | BCPAP2  | AL583687        | -1.72        | B-cell receptor-associated protein 29 |
|                    | LMNB1   | NM_005573       | 1.70         | Lamin B1 |
|                    | EPB2    | NM_004431       | -1.69        | EPH receptor A2 |
|                    | PHLD1A  | AK026181        | -1.68        | Pleckstrin homology-like domain, family A, member 1 |
|                    | ALDH1A3 | NM_000693       | -1.67        | Aldehyde dehydrogenase 1 family, member A3 |
|                    | ALKBH1  | A1922200        | -1.67        | AlkB, alkylation repair homolog 1 (E. coli) |
|                    | SOX4    | AI989477        | -1.67        | SRY (sex determining region Y)-box 4 |
|                    | MEF2C   | NN2468          | -1.66        | Myocyte enhancer factor 2C |
|                    | RNF130  | AL831873        | -1.64        | Ring finger protein 130 |
|                    | CDKN2D  | U20498          | -1.63        | Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) |
|                    | FOSL1   | BG251266        | -1.58        | FOS-like antigen 1 |
|                    | TRIM24  | NM_015905       | -1.57        | Tripartite motif-containing 24 |
|                    | SPHK1   | NM_021972       | -1.56        | Sphingosine kinase 1 |
|                    | BMP2    | NM_001200       | -1.55        | Bone morphogenetic protein 2 |
|                    | CDC2    | AL524035        | -1.54        | Cell division cycle 2, G1 to S and G2 to M |
|                    | CRADD   | U79115          | -1.53        | CASP2 and RIPK1 domain containing adaptor with death domain |
|                    | EXP11   | D79987          | -1.53        | extra spindle pole bodies homolog 1 (S. cerevisiae) |
|                    | PHLD1A  | NM_007350       | -1.52        | Pleckstrin homology-like domain, family A, member 1 |
|                    | MAP1S   | NM_018174       | -1.52        | Microtubule-associated protein 1S |
|                    | MCL1    | BF594464        | 2.33         | Myeloid cell leukemia sequence 1 (BCL2-related) |
|                    | B4GALT1 | M22921          | 2.20         | UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 1 |
|                    | MX1     | NM_002462       | 2.02         | Myxovirus resistance 1, interferon-inducible protein p78 (mouse) |
|                    | FGFR2   | M80634          | 1.99         | Fibroblast growth factor receptor 2 |
|                    | TXNIP   | AA812232        | 1.82         | Thioredoxin interacting protein |
|                    | TGFBR1  | AV700621        | 1.74         | Transforming growth factor, beta receptor 1 |
|                    | ARBB2   | NM_004313       | 1.61         | Arrestin, beta 2 |
|                    | SMAD3   | BF971416        | 1.55         | SMAD family member 3 |
Table 1. Differentially expressed genes in PC-treated OA chondrocytes compared with untreated OA chondrocytes.

| Gene ID | Gene Identifier | Fold change* | Description |
|---------|-----------------|--------------|-------------|
| TGFBR1  | AV700621        | 1.74         | Transforming growth factor, beta receptor 1 |
| ARRB2   | NM_004313       | 1.61         | Arrestin, beta 2 |
| C5orf13 | U36189          | 1.59         | Chromosome 5 open reading frame 13 |
| SMURF1  | AC004893        | 1.57         | SMAD specific E3 ubiquitin protein ligase 1 |
| SMAD3   | BF971416        | 1.55         | SMAD family member 3 |
| FGFR2   | M80634          | 1.99         | Fibroblast growth factor receptor 2 |
| RSAD2   | AW189843        | 1.63         | Radical S-adenosyl methionine domain containing 2 |
| PDLIM7  | AW206786        | 1.57         | PDZ and LIM domain 7 (enigma) |
| SMURF1  | AC004893        | 1.57         | SMAD specific E3 ubiquitin protein ligase 1 |
| IGFBP5  | R73554          | 1.53         | Insulin-like growth factor binding protein 5 |
| ENPP1   | BF057080        | -1.66        | Ectonucleotide pyrophosphatase/phosphodiesterase 1 |
| BMP2    | NM_001200       | -1.55        | Bone morphogenetic protein 2 |

*Negative number indicates decreased expression and positive number indicates increased expression (fold change) in PC-treated OA chondrocytes compared with untreated OA chondrocytes.

Table 2. Differentially expressed genes in PC-treated OA chondrocytes.

| Gene ID | Gene Identifier | Fold change* | Description |
|---------|-----------------|--------------|-------------|
| FABP4  | NM_001442       | -2.11        | Fatty acid binding protein 4, adipocyte |
| IRAK2  | AI246590        | -1.71        | Interleukin-1 receptor-associated kinase 2 |
| IL1RAP | AF167343        | -1.57        | Interleukin 1 receptor accessory protein |
| BMP2   | NM_001200       | -1.55        | Bone morphogenetic protein 2 |
| B4GALT1| M22921          | 2.20         | UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 1 |
| FN1    | AJ276395        | 1.92         | Fibronectin 1 |
| DLX2   | NM_004405       | -2.37        | Distal-less homeobox 2 |
| PCGF2  | NM_007144       | -1.89        | Polycomb group ring finger 2 |
| EPHA2  | NM_004431       | -1.69        | EPH receptor A2 |
| POSTN  | AW137148        | -1.56        | Periostin, osteoblast specific factor |
| BMP2   | NM_001200       | -1.55        | Bone morphogenetic protein 2 |
| FGFR2  | M80634          | 1.99         | Fibroblast growth factor receptor 2 |
| TGFBR1 | AV700621        | 1.74         | Transforming growth factor, beta receptor 1 |
| RDH10  | NM_172037       | 1.62         | Retinol dehydrogenase 10 (all-trans) |
| APCDD1 | N48299          | -2.68        | Adenomatosis polyposis coli down-regulated 1 |
| NDP    | NM_000266       | -2.30        | Norrie disease (pseudoglioma) |
| CCND1  | BC000076        | -1.68        | Cyclin D1 |
| SOX4   | AJ989477        | -1.67        | SRY (sex determining region Y)-box 4 |
| FZD8   | AB034703        | -1.58        | Frizzled homolog 8 (Drosophila) |
| BMP2   | NM_001200       | -1.55        | Bone morphogenetic protein 2 |
| FGFR2  | M80634          | 1.99         | Fibroblast growth factor receptor 2 |
| SMAD3  | BF971416        | 1.55         | SMAD family member 3 |

*Negative number indicates decreased expression and positive number indicates increased expression (fold change) in PC-treated OA chondrocyte compared with the untreated OA chondrocytes.
As shown in Table 1, the expression of numerous genes classified in proliferation and apoptosis was down-regulated by PC. Of the 39 differentially-expressed genes classified in cell proliferation, the expression of 30 genes, including lymphoid-specific helicase (HELLS, -2.32 fold) and interleukin 7 (IL-7, -1.82 fold), was down-regulated by PC. Of the 38 differentially-expressed genes classified in apoptosis, the expression of 30 genes, including sprouty homolog 2 (SPRY2, -1.92 fold) and baculoviral IAP repeat-containing 5 (BIRC5, -1.76 fold), was down-regulated by PC. In contrast, the expression of many genes classified in the transforming growth factor β (TGF-β) receptor signaling pathway and ossification were upregulated by PC. Of the 5 differentially-expressed genes classified in the TGF-β receptor signaling pathway, the expression of all 5 genes, including TGF-beta receptor 1 (TGFBR1, 1.74 fold), SMAD specific E3 ubiquitin protein ligase 1 (SMURF1, 1.57 fold), and SMAD family member 3 (SMAD3, 1.55 fold), was up-regulated by PC. Of the 7 differentially-expressed genes classified in ossification, the expression of 5 genes, including fibroblast growth factor receptor 2 (FGFR2, 1.99 fold), PDZ and LIM domain 7 (PDLIM7, 1.57 fold), and insulin-like growth factor binding protein 5 (IFGBP5, 1.53 fold), was up-regulated by PC. However, ectonucleotide pyrophosphatase 1 (ENPP1, -1.66 fold) and bone morphogenetic protein 2 (BMP2, -1.55 fold), two genes implicated in promoting ossification, was down-regulated by PC.

The expression of many genes classified in the inflammatory response, skeletal system development, and Wnt receptor signaling pathway was also downregulated by PC (Table 2). Of the 6 differentially-expressed genes classified in the inflammatory response, the expression of 4 genes, including fatty acid-binding protein 4 (FABP4; -2.11 fold), interleukin-1 receptor-associated kinase 2 (IRAK2, -1.71), and interleukin 1 receptor accessory protein (IL1RAP, -1.57), were down-regulated by PC of the 8 differentially-expressed genes classified in skeletal system development, the expression of 5 genes, including distal-less homeobox 2 (DLX2, -2.37 fold) and periostin (POSTN, -1.56 fold) was down-regulated by PC, of the 8 differentially-expressed genes classified in the Wnt receptor signaling pathway, the expression of 6 genes, including adenomatosis polyposis coli down-regulated 1 (APCDD1, -2.68 fold), norrie disease (NDP, -2.30 fold), and frizzled homolog 8 (FZD8, -1.58 fold), was down-regulated by PC.

### 3.2. Real-Time RT-PCR

Real-time RT-PCR was performed to confirm the differential expression of selected genes. As shown in Table 3, the differential expression of the genes examined was confirmed by real-time RT-PCR (P < 0.01).

| Gene ID | Gene Identifier | Differential Expression Microarray | Differential Expression RT-PCR |
|---------|-----------------|-----------------------------------|--------------------------------|
| HELLS   | NM_018063       | -2.32                             | -2.97                          |
| NDP     | NM_000266       | -2.30                             | -2.01                          |
| CCND1   | BC000076        | -1.68                             | -2.03                          |
| IL7     | NM_000880       | -1.82                             | -1.75                          |
| ENPP1   | BF057080        | -1.66                             | -1.92                          |
| FABP4   | NM_001442       | -2.11                             | -1.81                          |
| THBD    | NM_000361       | -2.57                             | -2.04                          |
| PLAT    | NM_000930       | -2.34                             | -2.50                          |
| FGFR2   | M80634           | 1.99                              | 2.34                           |
| SMAD3   | BF971416        | 1.55                              | 1.45                           |
| IGFBP5  | R73554           | 1.53                              | 1.67                           |

### 3.3. PC Inhibits Proliferation of OA Chondrocytes

The down-regulatory effect of PC on the expression of numerous genes classified in cell proliferation suggests that PC inhibits the proliferation of OA chondrocytes. Indeed, there were roughly 45% fewer OA chondrocytes in the wells containing PC compared to the wells containing no PC Fig. (1). The morphology of OA chondrocytes in the wells with and without PC was similar and trypan blue test showed little dead cells in both the untreated and PC-treated chondrocytes (not shown).
3.4. PC Inhibits OA Chondrocyte-Mediated Calcification

To investigate the OA chondrocyte-mediated calcification, we cultured OA chondrocytes in osteogenic differentiation medium. As shown in Fig. (2), calcium deposits were detected in the monolayer of OA chondrocytes cultured in osteogenic differentiation medium in the absence of PC, but not in the presence of 1 mm PC. These findings demonstrated that OA chondrocytes were capable of producing calcium crystals and that PC inhibited this calcification process.

3.5. PC Stimulates the Production of Cartilaginous Extracellular Matrices

Representative images of untreated and PC-treated micromasses of OA chondrocytes are provided in Fig. (3). As shown, the intensity of picrosirius red staining in the outer layer of the PC-treated micromass of OA chondrocytes was
higher than the intensity of picrosirius red staining in the outer layer of the untreated micromass, indicating that PC stimulated the production of collagens by OA chondrocytes. The intensity of alcian blue staining in the outer layer of the PC-treated micromass of OA chondrocytes was also higher than the intensity of alcian blue staining in the untreated micromass, indicating that PC also stimulated the production of proteoglycans by OA chondrocytes.

5. DISCUSSION

Increased number and size of chondrocyte clusters are hallmark histological features of OA articular cartilage [28, 29]. The number of proliferating chondrocytes increased during OA progression [29, 30] and the clusters contained apoptotic chondrocytes [29 - 32]. One of the potential mechanisms of apoptosis is abnormal differentiation of OA chondrocytes and subsequent calcification [33, 34]. OA cartilage showed co-localization of chondrocyte clusters and calcium deposits adjacent to apoptotic chondrocytes [35]. These previous findings indicate that chondrocyte activation, differentiation, calcification, and apoptosis are mutually linked OA disease processes. In this study, we demonstrate that PC downregulated the expression of numerous genes classified in proliferation and apoptosis in OA chondrocyte culture in the absence of calcium crystals. Consistent with its gene expression-regulatory effects, PC inhibited the proliferation of OA chondrocytes and chondrocyte-mediated calcification. These findings together indicate that PC can act directly on OA chondrocytes (a crystal-independent action of PC) in addition to calcium crystals (a crystal-dependent action of PC). PC may exert its OA disease-modifying activity, in part, by targeting genes involved in chondrocyte activation, apoptosis, and calcification, and in so doing, inhibiting chondrocyte apoptosis and chondrocyte-mediated calcification [36, 37].

Several previous findings appeared to be consistent with this new molecular mechanism. For examples, IL-7 (classified in proliferation) level was higher in OA chondrocytes and stimulated the production of MMP-13 [38]; HELLS (classified in proliferation and apoptosis) promoted cell activation [39]; BIRC5 (classified in apoptosis) was observed in chondrocytes within degraded lesions and was positively associated with apoptotic chondrocytes [40]. In this study, we demonstrated that PC down-regulated the expression of these 3 genes: IL-7, HELLS, and BIRC5. In addition, a recent study demonstrated that signaling via TGFBR1 (Smad2/3 route) resulted in a protective response whereas signaling via activin A receptor type II-like 1 (ACVRL1) (Smad1/5/8 route) resulted in a deleterious response in articular chondrocytes [41]. The ratio of ACVRL1/TGFBR1 was significantly increased in the cartilage of aging mice, favoring TGF-β signaling via the Smad1/5/8 route, inducing changes in chondrocyte differentiation and MMP-13 expression [41]. These previous findings indicate that reduced signaling via TGFBR1 (Smad2/3 route) may play a role in OA. Studies also demonstrated that inhibition of SMURF1-mediated degradation of Smad1/5 increased BMP-2 signal responsiveness and enhanced osteoblastic activity [42] and that intracellular delivery of SMURF1 inhibited BMP-2-induced alkaline phosphatase activity and downregulated BMP receptors [43, 44]. Remarkably, PC upregulated the
expression of TGFRB1, Smad3, and SMURF1 in the OA chondrocytes. This up-regulatory effect indicates that PC may exert its OA disease modifying effect or chondroprotective effects, in part, by enhancing the signaling via the TGFRB1 and Smad2/3 route while suppressing the signaling via IL-7, Smad1/5, and BMP-2 route.

Previous studies showed that inhibition of IGFBP5 proteolysis reduced articular cartilage degeneration [45 - 47], PDLIM7 inhibited MMP production [48], and that the expression of FGFR2 was decreased in degenerated cartilage [49]. These previous findings indicate that IGFBP5, PDLIM7, and FGFR2 are potentially chondroprotective proteins. In contrast, BMP-2 is potentially a disease candidate gene. The level of BMP-2 was elevated in serum, synovial fluid, and chondrocytes derived from OA patients and BMP2 induced chondrocyte hypertrophy and osteophyte formation [50 - 52]. Here, we demonstrated that PC up-regulated the expression of IGFBP5, PDLIM7, and FGFR2 while downregulated the expression of BMP2. This differential effect of PC on the expression of these genes indicates that PC may exert its OA disease modifying effect, in part, by stimulating the production of chondroprotective proteins and inhibiting pathological ossification stimulated by BMP2.

Of the genes classified in the inflammatory response, skeletal system development, and wnt receptor signaling pathways, PC downregulated the expression of FABP4, IRAK2, DLX2, POSTN, APCDD1, NDP, SOX4, and FZD8. These genes have either been previously implicated in arthritis or terminal differentiation of chondrocytes. For example, serum FABP4 was increased in patients with rheumatoid arthritis and metabolic syndrome [53, 54]; DLX2 promoted osteogenic differentiation of stem cells and enhanced mineralization [55]; POSTN induced the expression of IL-6, IL-8, and MMPs [56]; APCDD1 was associated with increased expression of Runx2 and elevated alkaline phosphatase activity [57]; NDP activated Wnt/β-catenin pathway associated with OA [58, 59]; SOX-4 signaling resulted in repression of SOX-9, a master transcription factor critical for chondrogenesis [60]; Silence of FZD8 resulted in decreased expression of MMP-3 [61]. The downregulation of the expression of these genes by PC was consistent with its OA disease-modifying activity.

CONCLUSION

In conclusion, PC can act directly on OA chondrocytes in the absence of calcium crystals. PC may exert its OA disease modifying effect, in part, through a crystal-independent mechanism or by inhibiting the expressions of genes implicated in chondrocyte activation, proliferation, apoptosis, calcification, and inflammatory response while stimulating the expressions of many genes implicated in chondroprotection and matrix production in chondrocytes.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

This study is supported in part by a Charlotte-Mecklenburg Education and Research Foundation Grant (to YS).

REFERENCES

[1] Hellio Le Graverand-Gastineau MP. OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed? Osteoarthritis Cartilage 2009; 17(11): 1393-401. [http://dx.doi.org/10.1016/j.joca.2009.04.009] [PMID: 19426849]

[2] Barrage PS, Brinckerhoff CE. Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. Curr Drug Targets 2007; 8(2): 293-303. [http://dx.doi.org/10.2174/138945007779940098] [PMID: 17305507]

[3] Calich AL, Domiciano DS, Fuller R. Osteoarthritis: can anti-cytokine therapy play a role in treatment? Clin Rheumatol 2010; 29(5): 451-5. [http://dx.doi.org/10.1007/s10067-009-1352-3] [PMID: 20108016]

[4] Malemud CJ. Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging 2010; 27(2): 95-115. [http://dx.doi.org/10.2165/11139950-000000000-00000] [PMID: 2014937]

[5] Nalbant S, Martinez JA, Kitummuayong T, Clayburne G, Sieck M, Schumacher HR Jr. Synovial fluid features and their relations to osteoarthritis severity: new findings from sequential studies. Osteoarthritis Cartilage 2003; 11(1): 50-4. [http://dx.doi.org/10.1053/joca.2002.0861] [PMID: 12505487]

[6] Fuerst M, Bertrand J, Lammers L, et al. Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum 2009; 60(9): 2694-703. [http://dx.doi.org/10.1002/art.24774] [PMID: 19714647]

[7] Sun Y, Mauerhan DR, Honeycutt PR, et al. Calcium deposition in osteoarthritic meniscus and meniscal cell culture. Arthritis Res Ther 2010; 12(2): R56.
[8] McCarthy GM, Mitchell PG, Cheung HS. The mitogenic response to stimulation with basic calcium phosphate crystals is accompanied by induction and secretion of collagenase in human fibroblasts. Arthritis Rheum 1991; 34(8): 1021-30.

[9] Sun Y, Wengler L, Brinckerhoff CE, Misra RR, Cheung HS. Basic calcium phosphate crystals induce matrix metalloproteinase-1 through the Ras/mitogen-activated protein kinase-e-Fos/AP-1/metalloproteinase 1 pathway. Involvement of transcription factor binding sites AP-1 and PEA-3. J Biol Chem 2002; 277(2): 1544-52.

[10] Ea HK, Uzan B, Rey C, Liòt F. Octacalcium phosphate crystals directly stimulate expression of inducible nitric oxide synthase through p38 and JNK mitogen-activated protein kinases in articular chondrocytes. Arthritis Res Ther 2005; 7(5): R915-26.

[11] Morgan MP, Whelan LC, Sallis JD, McCarthy CJ, Fitzgerald DJ, McCarthy GM. Basic calcium phosphate crystal-induced prostaglandin E2 production in human fibroblasts: role of cyclooxygenase 1, cyclooxygenase 2, and interleukin-1beta. Arthritis Rheum 2004; 50(5): 1642-9.

[12] McCarty DJ. Crystal-induced inflammation of the joints. Annu Rev Med 1970; 21: 357-66.

[13] Ea HK, Chobaz V, Nguyen C, et al. Pathogenic role of basic calcium phosphate crystals in destructive arthropathies. PLoS One 2013; 8(2): e57352.

[14] Nair D, Misra RP, Sallis JD, Cheung HS. Phosphocitrate inhibits a basic calcium phosphate and calcium pyrophosphate dihydrate crystal-induced mitogen-activated protein kinase cascade signal transduction pathway. J Biol Chem 1997; 272(30): 18920-5.

[15] Cheung HS, Sallis JD, Struve JA. Specific inhibition of basic calcium phosphate and calcium pyrophosphate crystal-induction of metalloproteinase synthesis by phosphocitrate. Biochim Biophys Acta 1996; 1315(2): 105-11.

[16] Sun Y, Reuben P, Wengler L, Sallis JD, Demadis KD, Cheung HS. Inhibition of calcium phosphate-DNA coprecipitates induced cell death by phosphocitrates. Front Biosci 2005; 10: 803-8.

[17] Cheung HS. Phosphocitrate as a potential therapeutic strategy for crystal deposition disease. Curr Rheumatol Rep 2001; 3(1): 24-8.

[18] Cheung HS, Sallis JD, Demadis KD, Wierzbicki A. Phosphocitrate blocks calcification-induced articular joint degeneration in a guinea pig model. Arthritis Rheum 2006; 54(8): 2452-61.

[19] Sun Y, Mauerhan DR, Franklin AM, Norton J, Hanley EN Jr, Gruber HE. Phosphocitrate is potentially a disease-modifying drug for noncrystal-associated osteoarthritis. Biomed Res Int 2013.

[20] Sun Y, Roberts A, Mauerhan DR, Sun AR, Norton HJ, Hanley EN Jr. Biological activities of phosphocitrate: a potential meniscal protective agent. Biomed Res Int 2013.

[21] Sun Y, Mauerhan DR, Steuerwald NM, Ingram J, Kneisl JS, Hanley EN Jr. Expression of phosphocitrate-targeted genes in osteoarthritis menisci. Biomed Res Int 2014.

[22] Sun Y, Haines N, Roberts A, et al. Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis. BMC Musculoskelet Disord 2015; 16: 270.

[23] Turhanen PA, Demadis KD, Peräniemi S, Vepsäläinen JJ. A novel strategy for the preparation of naturally occurring phosphocitrate and its partially esterified derivatives. J Org Chem 2007; 72(4): 1468-71.

[24] Sun Y, Mauerhan D, Hanley EN, Gruber H. Analysis of Meniscal Degeneration and Meniscal Gene Expression BMC Musculoskeletal Disorder 2010; 11(19)

[25] Reuben PM, Wengler L, Cruz M, Cheung HS. Induction of matrix metalloproteinase-8 in human fibroblasts by basic calcium phosphate and calcium pyrophosphate dihydrate crystals: effect of phosphocitrate. Connect Tissue Res 2001; 42(1): 1-12.

[26] Cheung HS, Sallis JD, Mitchell PG, Struve JA. Inhibition of basic calcium phosphate crystal-induced mitogenesis by phosphocitrate. Biochem Biophys Res Commun 1990; 171(1): 20-5.

[27] Sun Y, Mauerhan DR, Franklin AM, Zinchenko N, Norton HJ, Hanley EN Jr, et al. Fibroblast-like synoviocytes induce calcium mineral
formation and deposition. Arthritis 2014. [http://dx.doi.org/10.1155/2014/812678]

[28] Mankin HJ, Lippiello L. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. J Bone Joint Surg Am 1970; 52(3): 424-34. [http://dx.doi.org/10.2106/00004623-197052030-00002] [PMID: 4246573]

[29] Lotz MK, Otsuki S, Grogan SP, Sah R, Terkeltaub R, DLima D. Cartilage cell clusters. Arthritis Rheum 2010; 62(8): 2206-18. [http://dx.doi.org/10.1002/art.27528] [PMID: 20506158]

[30] Pfänder D, Körtje D, Weseloh G, Swoboda B. [Cell proliferation in human arthrotic joint cartilage]. Z Orthop Ihre Grenzgeb 2001; 139(5): 375-81. [Cell proliferation in human arthrotic joint cartilage]. [http://dx.doi.org/10.1055/s-2001-17977] [PMID: 11605286]

[31] Hashimoto S, Ochs RL, Komiya S, Lotz M. Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. Arthritis Rheum 1998; 41(9): 1632-8. [http://dx.doi.org/10.1002/1529-0131(199809)41:9<1632::AID-ART14-3.0.CO;2-A] [PMID: 9751096]

[32] Blanco FJ, Guitian R, Vázquez-Martul E, de Toro FJ, Galdo F. Osteoarthritis chondrocytes die by apoptosis. A possible pathway for osteoarthritis pathology. Arthritis Rheum 1998; 41(2): 284-9. [http://dx.doi.org/10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T] [PMID: 9485086]

[33] von der Mark K, Kirsch T, Nerlich A, et al. Type X collagen synthesis in human osteoarthritic cartilage. Indication of chondrocyte hypertrophy. Arthritis Rheum 1992; 35(7): 806-11. [http://dx.doi.org/10.1002/178035015] [PMID: 1622419]

[34] Pullig O, Weseloh G, Ronneberger D, Käkönen S, Swoboda B. Chondrocyte differentiation in human osteoarthrosis: expression of osteocalcin in normal and osteoarthritic cartilage and bone. Calcif Tissue Int 2000; 67(3): 230-40. [http://dx.doi.org/10.1007/s002230010108] [PMID: 10594778]

[35] Johnson K, Hashimoto S, Lotz M, Pritzker K, Goding J, Terkeltaub R. Up-regulated expression of the phosphodiesterase nucleotide pyrophosphatase family member PC-1 is a marker and pathogenic factor for knee meniscal cartilage matrix calcification. Arthritis Rheum 2001; 44(5): 1071-81. [http://dx.doi.org/10.1002/1529-0131(200105)44:5<1071::AID-ANT187>3.0.CO;2-3] [PMID: 11352238]

[36] Cheung HS, Kurup IV, Sallis JD, Ryan LM. Inhibition of calcium pyrophosphate dihydrate crystal formation in articular cartilage vesicles and cartilage by phosphocitrate. J Biol Chem 1996; 271(45): 28082-5. [http://dx.doi.org/10.1074/jbc.271.45.28082] [PMID: 8910421]

[37] Cheung HS, Ryan LM. Phosphocitrate blocks nitric oxide-induced calcification of cartilage and chondrocyte-derived apoptotic bodies. Osteoarthritis Cartilage 1999; 7(4): 409-12. [http://dx.doi.org/10.1013/joca.1998.0227] [PMID: 10419783]

[38] Van Roon JA, Lefeber FP. Role of interleukin-7 in degenerative and inflammatory joint diseases. Arthritis Res Ther 2008; 10(2): 107. [http://dx.doi.org/10.1186/ar2395] [PMID: 18466642]

[39] Von Eys B, Maaskola J, Memczak S, et al. The SNF2-like helicase HELLs mediates E2F3-dependent transcription and cellular transformation. EMBO J 2012; 31(4): 972-85. [http://dx.doi.org/10.1038/emboj.2011.451] [PMID: 22157815]

[40] Zhao H, Qiu GX, Guan J, Zhao Y, Zhou X. [Correlation of apoptosis of articular chondrocytes in osteoarthritis with degree of cartilage destruction and expression of apoptosis-related proteins: surviving, caspase-3, and Bcl-xl]. Zhonghua Yi Xue Za Zhi 2008; 88(19): 1339-41. [PMID: 18956705]

[41] Van der Kraan PM. Age-related alterations in TGF beta signaling as a causal factor of cartilage degeneration in osteoarthritis. Biomed Mater Eng 2014; 24(1)(Suppl.): 75-80. [PMID: 24928920]

[42] Cao Y, Wang C, Zhang X, et al. Selective small molecule compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation. Sci Rep 2014; 4: 4965. [http://dx.doi.org/10.1038/srep04965] [PMID: 24828823]

[43] Hsu CW, Liu S, Hsa E, Hollinger JO. Inhibition of rhBMP-2-induced ALP activity by intracellular delivery of SMURF1 in murine calvarial preosteoblast cells. J Biomed Mater Res A 2014; 102(11): 4037-43. [http://dx.doi.org/10.1002/jbm.a.35046] [PMID: 24288199]

[44] Murakami K, Mathew R, Huang J, et al. Smurf1 ubiquitin ligase causes downregulation of BMP receptors and is induced in monocrotaline and hypoxia models of pulmonary arterial hypertension. Exp Biol Med (Maywood) 2010; 235(7): 805-13. [http://dx.doi.org/10.1258/ebm.2010.009383] [PMID: 20558834]

[45] Okabe T, Ohmori Y, Tanigami A, et al. Detection of gene expression in synovium of patients with osteoarthritis using a random sequencing method. Acta Orthop 2007; 78(5): 687-92. [http://dx.doi.org/10.1080/1745367070144400] [PMID: 17966030]

[46] Busby WH Jr, Yocom SA, Rowland M, et al. Complement C1s is the serine protease that cleaves IGFBP-5 in human osteoarthritic joint fluid. Osteoarthritis Cartilage 2009; 17(4): 547-55. [http://dx.doi.org/10.1016/j.joca.2008.08.004] [PMID: 18930415]
[47] Clemmons DR, Busby WH Jr, Garmong A, et al. Inhibition of insulin-like growth factor binding protein 5 proteolysis in articular cartilage and joint fluid results in enhanced concentrations of insulin-like growth factor 1 and is associated with improved osteoarthritis. Arthritis Rheum 2002; 46(3): 694-703. [http://dx.doi.org/10.1002/art.10222] [PMID: 11920405]

[48] Liu H, Pan H, Yang H, et al. LIM mineralization protein-1 suppresses TFN-α induced intervertebral disc degeneration by maintaining nucleus pulposus extracellular matrix production and inhibiting matrix metalloproteinases expression. J Orthop Res 2015; 33(3): 294-303. [http://dx.doi.org/10.1002/jor.22732] [PMID: 25336289]

[49] Jeffries MA, Donica M, Baker LW, et al. Genome-wide DNA methylation study identifies significant epigenomic changes in osteoarthritic cartilage. Arthritis Rheumatol 2014; 66(10): 2804-15. [http://dx.doi.org/10.1002/art.38762] [PMID: 24980887]

[50] Liu Y, Hou R, Yin R, Yin W. Correlation of bone morphogenetic protein-2 levels in serum and synovial fluid with disease severity of knee osteoarthritis. Med Sci Monit 2015; 21: 363-70. [http://dx.doi.org/10.12659/MSM.892160] [PMID: 25336289]

[51] Papathanasiou I, Malizos KN, Tsezou A. Bone morphogenetic protein-2-induced Wnt/β-catenin signaling pathway activation through enhanced low-density-lipoprotein receptor-related protein 5 catabolic activity contributes to hypertrophy in osteoarthritic chondrocytes. Arthritis Res Ther 2012; 14(2): R82. [http://dx.doi.org/10.1186/ar3805] [PMID: 221523174]

[52] Blaney Davidson EN, Vitters EL, Bennink MB, et al. Inducible chondrocyte-specific overexpression of BMP2 in young mice results in severe aggravation of osteophyte formation in experimental OA without altering cartilage damage. Ann Rheum Dis 2015; 74(6): 1257-64. [http://dx.doi.org/10.1136/annrheumdis-2013-204528] [PMID: 24448347]

[53] Andrés Cerezuela L, Kuklová M, Hulejová H, et al. The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels. Cytokine 2013; 64(1): 441-7. [http://dx.doi.org/10.1016/j.cytto.2013.05.001] [PMID: 23714112]

[54] Kralisch S, Fasshauer M. Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia 2013; 56(1): 10-21. [http://dx.doi.org/10.1007/s00125-012-2737-4] [PMID: 23052058]

[55] Qu B, Liu O, Fang X, et al. Distal-less homeobox 2 promotes the osteogenic differentiation potential of stem cells from apical papilla. Cell Tissue Res 2014; 357(1): 133-43. [http://dx.doi.org/10.1007/s00441-014-1833-9] [PMID: 24756434]

[56] Chijimatsu R, Kunizuka Y, Taniyama Y, Nakamura N, Tomita T, Yoshikawa H. Expression and pathological effects of periostin in human osteoarthritis cartilage. BMC Musculoskelet Disord 2015; 16: 215. [http://dx.doi.org/10.1186/s12891-015-0682-3] [PMID: 26289167]

[57] Viale-Bouroncle S, Klingelhoeffer C, Ettl T, Morsczeck C. The WNT inhibitor APCDD1 sustains the expression of β-catenin during the osteogenic differentiation of human dental follicle cells. Biochem Biophys Res Commun 2015; 457(3): 314-7. [http://dx.doi.org/10.1016/j.bbrc.2014.12.107] [PMID: 25592970]

[58] Chang TH, Hsieh FL, Zebisch M, Harlos K, Elegeheert J, Jones EY. Structure and functional properties of Norrin mimic Wnt for signalling with Frizzled4, Lrp5/6, and proteoglycan. eLife 2015; 9: 4. [http://dx.doi.org/10.7554/eLife.06554] [PMID: 26158506]

[59] Corr M. Wnt-beta-catenin signaling in the pathogenesis of osteoarthritis. Nat Clin Pract Rheumatol 2008; 4(10): 550-6. [http://dx.doi.org/10.1038/ncprheum0904] [PMID: 18820702]

[60] Bhattacharyya P, Penzo-Méndez A, Kato K, et al. SOXC proteins amplify canonical WNT signaling to secure nonchondrocytic fates in skeletogenesis. J Cell Biol 2014; 207(5): 657-71. [http://dx.doi.org/10.1083/jcb.201405098] [PMID: 25452386]

[61] Miao CG, Shi WJ, Xiong YY, et al. miR-375 regulates the canonical Wnt pathway through FZD8 silencing in arthritis synovial fibroblasts. Immunol Lett 2015; 164(1): 1-10. [http://dx.doi.org/10.1016/j.imlet.2015.01.003] [PMID: 25619565]